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1. Introduction
Hepatocellular  carcinoma  (HCC)  is  the  third  leading  cause  of  cancer  mortality  world‐
wide, accounting for more than 500,000 deaths annually. Major risk factors include chronic
liver disease and liver cirrhosis  due to hepatitis  B and C viral  infections,  alcoholic  liver
disease and non-alcoholic steatohepatitis (NASH). Surgical resection and liver transplanta‐
tion are the only potentially curable options for patients with HCC. While surgical resection
is the treatment of choice in patients with good hepatic function, it  is contraindicated in
those with moderate to severe cirrhosis (Child class B or C),  leaving these patients with
liver  transplantation  as  the  only  option.  Moreover,  transplantation  is  the  optimal  treat‐
ment even for small, otherwise resectable disease. This is a reflection of a number of factors.
Liver transplantation will most likely result in a microscopically negative resection, which
is  the  most  effective  oncologic  treatment.  Most  HCCs  are  multifocal  especially  in  the
background of  cirrhosis,  though pre-neoplastic  lesions may not  be  visible  on periopera‐
tive  evaluation;  they are  likely  to  continue  to  evolve  into  new primary HCCs.  Further‐
more, transplantation eliminates cirrhosis and restores normal hepatic function. However,
limited organ availability mandates the restriction of liver transplantation to patients with
early stage tumors who are not candidates for resection.
2. Organ allocation
In an effort to prioritize liver transplant candidates according to the highest short-term risk
of mortality from end stage cirrhosis, the model for end-stage liver disease (MELD) scoring
system was implemented in 2002 (table 1). To impart more urgent access to liver transplan‐
tation  for  patients  with  small  HCCs,  additional  points  within  the  scoring  system  were
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allotted to these patients. This is done to equilibrate their risk of death in comparison with
the mortality of end-stage cirrhosis. The original scoring exception included lesions smaller
than 2 cm, which resulted in an over distribution of  donor livers to patients with HCC
(with many expected small tumors turning out not to be HCC on explanted pathology).
Therefore, the scoring exception was modified later by reducing the upgrade for Stage II
tumors  and  eliminating  it  for  Stage  I  tumors.  Using  the  American  Liver  Tumor  Study
Group Modified TNM staging system, current UNOS guidelines do not allow upgrading
of  candidates  with  Stage  I  disease,  irrespective  of  biopsy  confirmation;  only  candidates
with  Stage  II  HCC  disease  are  upgraded  on  the  waiting  list  to  a  MELD  score  of  22
(equivalent to a 15% probability of candidate death within 3 months) with the intent to
shorten  their  waiting  time.  From 2002-2007  in  UNOS database,  patients  with  an  “HCC
MELD-exception” had similar survival to patients without HCC.
MELD score component, calculation and mortality prediction
Serum bilirubin (mg/dL)
Serum creatinine (mg/dL)
INR
MELD = 3.8[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.6[Ln serum creatinine (mg/dL)] + 6.4
* If a patient has had 2 or more hemodialysis treatments or 24 hours of CVVHD in the week prior to the time of the
scoring, Creatinine will be set to 4 mg/dL
MELD score
- <9
- 10–19
- 20–29
- 30–39
- >40
Mortality in 3 months
1.9 %
6.0 %
19.6 %
52.6 %
71.3%
Table 1. MELD score component, calculation and mortality prediction
3. Criteria for transplantation
Retrospective study by Mazzaferro and colleagues established that favorable results could be
achieved in patients with cirrhosis with either a solitary HCC ≤5 cm or with up to 3 nodules
≤3 cm, criteria that came to be called ‘‘the Milan criteria (Table3).’’ The 5-year survival of these
early-stage patients exceeded 70%. Recipient age, gender, type of viral infection, or Child-Pugh
score (table 2) did not affect survival after transplantation. In a multivariate analysis by Marsh
JW and colleagues, found that independent predictors of tumor-free survival included lymph
node status, depth of vascular invasion, greatest tumor dimension, lobar distribution, and
tumor number.
The strict application of the Milan criteria by UNOS for MELD upgrades allocation disadvan‐
tages patients with HCC with tumor profiles exceeding the criteria’s maximal size or multifocal
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parameters but in whom favorable outcomes after liver transplantation have been demon‐
strated. There is an ongoing debate within the liver transplantation community regarding
whether to expand indications for liver transplantation as primary therapy for HCC. For
patients with HCC disease beyond Milan criteria in whom there is no macroscopic evidence
of vascular invasion or extrahepatic spread, the survival rates after liver transplantation are
generally comparable with patients transplanted for disease within the criteria. Most groups
report a 5-year survival of more than 50% in patients transplanted for HCC beyond Milan,
which many investigators have argued is the minimum acceptable survival rate. In 2001Yao
and colleagues at the University of California, San Francisco (UCSF) defined an expanded set
of HCC criteria (solitary tumor ≤ 6.5 cm, or ≤ 3 nodules with the largest tumor ≤ 4.5 cm and
total tumor diameter ≤ 8 cm)(table3) for which 1 and 5-year survival rates after LT were 90%
and 75%, respectively. Retrospectively evaluating post- liver transplantation survival for
patients with tumors beyond Milan criteria but within ‘‘UCSF’’ expanded criteria by pre-
transplantation imaging and explant pathology, the group at the University of California, Los
Angeles (UCLA) confirmed acceptable 1,3-, and 5-year survival rates of 82%, 65%, and 52%,
respectively. Moreover, the difference in 5-year recurrence-free survival after liver transplan‐
tation for HCC in the UCLA study did not reach statistical significance between Milan criteria
and UCSF expanded criteria tumor groups (74% vs 65%, P =.09). Liver transplantation in such
candidates is controversial and widely adopted. The short-term outcomes are similar to those
who are transplanted within the Milan criteria.
CHILD – PUGH SCORE
Clinical and laboratory
parameter
Scores
1 2 3
Encephalopathy (grade) None 1-2 3-4
Ascites None Slight Moderate
Albumin (g/dL) > 3.5 2.8-3.5 < 2.8
Prothrombin time
prolonged (sec)
1-4 4-6 6
Bilirubin (mg/dL)
· For primary biliary
cirrhosis
< 2
< 4
2-3
4-10
> 3
> 10
Class A = 5–6 points; Class
B = 7–9 points; Class C =
10–15 points.
Class A: Good operative
risk
Class B: Moderate
operative risk
Class C: Poor operative risk
Table 2. Child Pugh score
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Group from Edmonton have study Total Tumor Volume (TTV) in patients with HCC who had
liver transplant based on Milan or UCSF criteria in 3 centers and they found TTV < 115 cm3
has lower recurrence rate than TTV > 115 cm3. In same study they also found that patients
beyond Milan but within TTV < 115 cm3 had survivals similar to those of patients within Milan.
On the contrary, patients with TTV >115 cm3 demonstrated lower survival than those within
TTV <115 cm3 when pathology (5-year: 47% versus 79%, P < 0.001) and radiology staging (5-
year: 53% versus 76%, P < 0.1) was used.
Milan criteria:
- Single lesion ≤ 5 cm or
- ≤3 nodules each ≤ 3 cm
Without vascular invasion.
"UCSF’’ expanded criteria:
- Single lesion ≤ 6.5 cm or
- ≤ 3 nodules with the largest tumor ≤ 4.5 cm and total tumor diameter ≤ 8 cm
Without vascular invasion.
Table 3. Criteria for liver transplantation
4. Pre-transplant treatment for HCC
The major limitation for liver transplantation as therapy for early-stage HCC is the insufficient
number of donor livers. There is always a waiting period between candidate listing and
transplantation. If the waiting period extends over a sufficient length of time, the tumor will
grow and eventually hinders transplantation. In a study by Yao and colleagues of patients with
HCC on the waiting list, a 6-month waiting period for liver transplantation was associated
with a 7.2% cumulative dropout probability, increasing to 37.8% and 55.1% at 12 and 18
months, respectively. In this setting the treatment of HCC prior to liver transplantation has
three potential goals: (a) controlling tumor growth and vascular invasion during the waiting
time and therefore decrease dropouts from the waiting list; (b) carrying out neoadjuvant
therapy to improve the post-transplant outcome by reducing the risk of postoperative
recurrence, and (c) downstaging the HCC burden to make a patient eligible for transplantation.
Followups for patients on waiting list are required every three months by CT or MRI to ensure
continued eligibility for liver transplantation.
5. Percutaneous ablation therapy
5.1. Bridging therapy
Bridge therapy is used to decrease tumor progression and the dropout rate from the liver
transplantation waiting list. It is considered for patients who meet the transplant criteria. A
Hepatic Surgery356
number of studies have investigated the role of locoregional treatment as a bridge to liver
transplantation in patients on a waiting list. These studies included radiofrequency ablation
(RFA), transarterial chemoembolization (TACE), surgical resection, conformal radiation
therapy, and sorafenib as “bridge” therapies.
5.1.1. TACE
The rationale for using TACE as a bridge therapy prior to OLT is to control tumor growth
while the patient awaits an organ. In addition, TACE could cause significant tumor necrosis,
which may reduce tumor dissemination, making it a potential neoadjuvant therapy. TACE can
also be used to learn more about the natural history and behavior of a particular tumor prior
to liver transplantation. Decaens et al. failed to demonstrate survival benefit in a retrospective
case-control study comparing 100 patients who underwent TACE prior to liver transplantation
(median 1 session/patient) versus 100 matched controls without prior treatment. Mean waiting
time was 4.2 months, and 5-year post-LT survival rates were 69% versus 63% (p = ns); dropout
was not analyzed. Yao et al. retrospectively studied 168 HCC patients who underwent liver
transplantation, 88 of whom received TACE (in most cases immediately prior to LT). For
patients with HCC within the Milan criteria, 5-year recurrence-free survival was 96% for the
TACE group versus 87% for controls (p = 0.12), but for HCC beyond the Milan criteria the
difference was statistically significant (86% vs. 51%, p = 0.05). Roayaie et al. reported a 46%
dropout rate, but only advanced HCC (>5 cm) were included in this study. Graziadei et al. found
no dropout from the waiting list in patients treated wit TACE meeting Milan criteria and the
mean waiting time was only 178 days. Furthermore, the monitoring protocol of repeat staging
and the criteria for dropout was not specified. In view of this study and others, the dropout
rate ranged from 15 to 46%. The rate of dropout was related to the tumor state and to the
duration in the waiting list, the higher rate (46%) being observed in more advanced HCC and
when the mean waiting time was 340 days. A systematic review of bridging therapy with TACE
by Lesurtel et al. concluded that there was insufficient good quality evidence to demonstrate
that TACE either improved post-LT survival, altered post-LT complication rates, or impacted
on waitlist drop out.
Although pre-liver transplantation TACE does not influence post-LT overall survival and
disease-free survival, it remains indicated in context of clinical trial when the period on the
waiting list is more than 6 months.
5.1.2. Percutaneous ablation therapy
Patients with small tumors can have ablation either by percutaneous ethanol injection,
radiofrequency or any other technique. Pre-transplant RFA ablation for HCC as a strategy to
reduce dropout has been addressed in view studies. More than 80% of patients were in the
Milan criteria with approximately 1 year on the waiting list. The dropout rate ranged from 0
to 14%. In a nonrandomized series from Toronto of 74 patients bridged using ablation
compared with 79 non-bridged patients, the analysis of dropout for tumor progression
identified a difference (p < 0.005) that became apparent only with prolonged waiting time
superior to 300 days.
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The main concern with this approach is seeding due to tumor puncture as has been reported
for diagnostic biopsy. However, puncture-related seeding is usually a case of poorly differ‐
entiated tumors and to peripheral tumors that cannot be approached through a rim of non-
tumoral liver.
In conclusion, due to small size of these studies and the heterogeneous nature of the study
populations, as well as the absence of randomized clinical trials evaluating the utility of bridge
therapy for reducing the liver transplantation waiting list dropout rate, limit the conclusions
that can be drawn. Therefore, if liver transplantation can be done without significant delay
(i.e. within 6 month) would the optimum. However, in patients whose waiting time is
predicted to be prolonged, an RCT of TACE and/or ablation as bridging therapy to decrease
dropout of transplantation could be justified.
5.2. Liver resection
Advances in liver surgery have significantly improved the safety of resection. Resection can
be used as a treatment for HCC prior to liver transplantation in three different settings. First,
resection can be used as a primary therapy, and liver transplantation reserved as a ‘‘salvage’’
therapy for patients who develop recurrence or liver failure. A second justification for resection
prior to transplantation is that it helps refine the selection process. Resection, indeed, gives
access to detailed pathological examination of the tumor and the surrounding liver parenchy‐
ma. Important prognostic information can be obtained from the entire resected tumor,
including differentiation (which proved to be heterogeneous within the tumor), satellite
nodules, microvascular invasion, and capsular effraction. As a result, resection may help deny
transplantation in patients with tumors apparently within the Milano criteria but with
histological features of especially poor prognosis (undetected macrovascular invasion in
particular). On the other hand, resection may help decide transplantation in patients with
tumors slightly outside the Milano criteria but with histological features of good prognosis.
Third, resection can be used as a ‘‘bridge’’ therapy for patients who have already been enlisted
for liver transplantation. Resection as the first line treatment for patients with small HCC with
preserved liver function, followed by salvage transplantation only for recurrence or liver
failure is an attractive option. Initial resection with negative margins, gives rapid access to an
effective therapy, without the need for a donor, and offers 5-year survival rates exceeding 50%
with a good quality of life. The main obstacle to this strategy is the risk of ‘‘loss of chance’’ in
case of rapid and extensive recurrence not amendable to salvage liver transplantation. At the
time of recurrence, salvage liver transplantation is only applicable in patients with a tumor
within the Milan criteria. Initial data showed that patients with HCV infection who developed
recurrence after partial resection had multifocal tumors and/or vascular invasion at the time
of recurrence.
Although limited resection appears to be sufficient in this setting, it is associated with increased
risk of post resection liver failure and is only appropriate for patients with peripheral tumors and
Child A cirrhosis and no portal hypertension. As disadvantage for this approach the subse‐
quent liver transplantation would be more difficult due to increase operative time and blood loss.
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The use of laparoscopic approaches for peripheral tumors may further contribute to expand this
strategy by minimizing technical difficulties during the transplant procedure.
5.3. Tumor dowenstaging
The role of downstaging of tumors before liver transplantation has been explored. Downstag‐
ing is done using HCC directed therapy that aims at reducing the size and/or number of HCC
lesions. Graziadei et al. achieved downstaging to within Milan using TACE in 15/36 patients
(41%). Among those downstaged, four dropped out prior to LT, one remained waiting, and
10 underwent LT; there were six deaths including three HCC recurrences, and 4- year post-
transplant survival of 41%. Yao et al. reports successful downstaging in 21/30 patients with
HCC beyond UCSF using a multimodality approach including resection in four cases. There
were two deaths related to downstaging treatment (one postresection). Among 16 patients
transplanted there was one death and no recurrence, but follow-up was limited (median 16
months). Recent prospective studies have demonstrated that downstaging (prior to transplant)
with percutaneous ethanol injection (PEI), RFA, TACE and transarterial radioembolization
(TARE) with yttrium 90 microspheres improves disease-free survival following transplant.
However, such studies have used different selection criteria for the downstaging therapy and
different transplant criteria after successful downstaging. In some studies response to locore‐
gional therapy has been associated with good outcomes after transplantation. Further valida‐
tion is needed to define the end-points for successful downstaging prior to transplant.
6. Living donor transplantation
Efforts to address the large waiting list of liver transplantation candidates and to decrease the
dropout rate have included several strategies such as living donor LT, domino LT, split LT,
the use of extended criteria donors, and donors after cardiac death. Living donor LT appears
to be an effective option for patients with HCC within the Milan criteria, essentially equivalent
in terms of survival to OLT, and it is cost effective if waiting times exceed 7 months. There are
few data to support the use of living donor LT for patients with HCC who exceed the Milan
criteria, although its use for this purpose is becoming increasingly common.
7. Immunsupression
Immunsupresion is used post liver transplantation to reduce graft rejection but, especial‐
ly in transplantation for HCC, is associated with a risk of tumor growth. While results of
liver  transplantation  including  survival  and  rates  of  rejection  were  dramatically  im‐
proved  in  cyclosporine  treated  patients  compared  with  "historical  controls",  a  high
incidence of neoplasm and its aggressive phenotype were found to be due to cyclospor‐
ine and its activation of transforming growth factor-beta (TGFβ). Vivarelli  and colleagues
reported  an  increase  in  5-year  recurrence  free  survival  in  patients  treated  with  smaller
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cumulative doses of cyclosporine in the first year following liver transplantation for HCC.
Furthermore, they observed a significantly higher mean cyclosporine level in patients with
HCC recurrence. Tacrolimus, another calcineurin inhibitor was also found to promote cell
cycle progression by an increase in cdk4 kinase activity and thus was linked to increased
tumor recurrence.
On the other hand, the calcineurin-independent immunosuppressive agent sirolimus, a binder
of mTOR, inhibits tumor growth in cell lines, and it inhibits primary and metastatic tumor
growth in vivo. In a study by Wang Z et al, looking at HCC in mouse model of human HCC,
they identify that sirolimus induces cell cycle arrest and blocke proliferation of an HCC cell
line, also sirolimus found to prevent tumor growth and metastatic progression by down-
regulating the mRNA expression of VEGF and HIF-1α.
Several retrospective reports suggest a lower risk of post-transplant tumor recurrence in
patients with HCC with the use of sirolimus as compared to other types of immunosuppressive
agents (such as the calcineurin inhibitors tacrolimus and cyclosporine). However, these reports
are limited by small size and uncertainty as to whether the observed benefits were due to a
specific antitumor effect or an impact on liver transplant in general.
8. Surveillance
There is no consensus as to the optimal approach for post-transplant surveillance. Guidelines
from the National Comprehensive Cancer Network (NCCN) suggest the follow up after liver
transplant with triphasic CT every 3-6 months for 2 years, then every 6-12 months. AFP levels
every 3 months for 2 years, if initially elevated, then every 6-12 months.
9. Survival
There is a clear survival benefit and low recurrence rate after transplantation for hepatocellular
carcinoma. When surgeons adhere to Milan criteria, 5-year survival rates after transplantation
range from 70% to 80%, and tumor recurrence rates are approximately 10%. Since the initial
report by Yao and colleagues that demonstrated acceptable survival rates using the UCSF
criteria (90% 1-year survival rates and 75% 5-year survival rates) and showed no survival
deference from Milan criteria in 1,3 and 5 years, long-term survival need to be further identi‐
fied.
10. Recurrence
Tumor recurrence remains a main limitation to the long-term survival of patients following
liver transplantation for HCC. While the majority of patients recur in the first two years after
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transplantation, late recurrence is not infrequent. Most common sites of recurrence are liver
graft, lung, bone, abdominal lymph nodes, adrenal glands and peritoneum. The incidence of
recurrent HCC following transplantation has been reported to vary, ranging from 6-56%.
However, in cases in which the Milan selection criteria were adopted, risk of recurrence
decreased to 10–15% at 5 years. While several recipient and tumor specific factors are prog‐
nostically important, primary tumor size, number of lesions, grade of tumor and presence of
vascular invasion have been noted to be the most significan clinical risk factors for both
recurrence and survival. De-novo tumor development from recurrent hepatitis and cirrhosis
in the liver graft can occur, however presence of microscopic foci of disease in lymph nodes
or distant organs at the time of transplantation, as well as hematogenous or peritoneal tumor
dissemination during transplantation, are mechanisms attributed to disease recurrence.
Recurrent disease following liver transplantation for HCC may involve an extrahepatic site in
10-43% of patients.
Successful surgical salvage has been reported for intrahepatic and/or confined extrahepatic
HCC metastases. In a study by Regalia et al, involving several Italian centers, 7 out of 21 patients
(30%) underwent salvage resection of recurrent HCC of the liver (2), lung (2), bone (1), skin or
other sites (2). Surgical resection was associated with a survival of 15.5 months, which was
better than the 5.5 months noted among patients treated with a non-surgical approach. Schlitt
et al. reported on 39 patients with recurrent disease, 9 intrahepatic recurrences, 15 extrahepatic
disease and 15 had both intra and extrahepatic recurrence. Eleven of these patients were able
to undergo complete removal of the recurrent disease, including 5 patients with an intrahepatic
recurrence; 7 (63%) were alive at 4.3 years of follow-up. As with HCC of the native liver, the
utilization of resection versus ablation to treat recurrence in the allograft is dependent on
surgical judgment, as well as the size and location of the tumor. While resection may be more
applicable to more superficial and larger tumors, ablative techniques may be sufficient and
appropriate in the setting of smaller and more deeply situated tumors. Although liver resection
for intrahepatic HCC recurrence has been reported by several centers, most series are limited
by a small sample size.
Reports of repeat liver transplantation as a treatment of recurrent intrahepatic HCC are limited
to a few very select case series and is not the standard of care.
Another potential approach to intrahepatic HCC recurrence is the utilization with TACE and
RFA. Ko et al, reported on 28 patients with recurrent HCC who underwent one or more cycles
of TACE after transplantation (mean, 2.5 cycles). In this study, the targeted tumor reduced in
size by ≥25% in 19 of the 28 study patients (68%). However, intrahepatic or extrahepatic
metastasis occurred in 21 of the 28 patients (75%) during the 3-month follow-up period and
mean survival was only 9 months.
Systemic therapeutic options for recurrent HCC are limited. While cytotoxic agents have
traditionally had marginal effect in the treatment of HCC, systemic therapy with molecular
targeted therapy has been shown to prolong survival in recent trials. Sorafenib, a multi-
targeted kinase inhibitor, demonstrated a significant overall survival benefit in patients with
advanced or metastatic HCC when compared with placebo in two separate Phase 3 trials. These
studies were carried out in patients who presented initially with advanced disease (mostly
Transplantation for Hepatocellular Carcinoma
http://dx.doi.org/10.5772/54174
361
liver confined disease), and did not include patients who had previously undergone curative-
intent therapy, such as surgical resection or liver transplantation. A number of retrospective
studies have reported acceptable safety data for sorafenib in liver transplant patients, with
very few unexpected toxicities or interaction with immunosuppressive medications. The
numbers in these studies are small, and there is clearly a need for a prospective trial to fully
assess the potential survival benefit of sorafenib in this setting.
Radiation therapy is another option for patients with recurrent unresectable HCC. Three
dimensional conformal radiation, as well as stereotactic body radiation therapy and radioem‐
bolization, have been utilized in the treatment of primary unresectable HCC. In addition,
radiation therapy is a treatment option for symptomatic palliation of extrahepatic disease.
Yamashi et al, reported on 28 patients with metastatic HCC involving the portal and/or
peripancreatic lymph nodes who were treated with radiation therapy. A total of 18 (64%) and
five (18%) patients achieved partial responses and complete responses, respectively. The 1-
and 2-year overall survival rates were 53% and 33%, respectively. In one study, Seong et al.
investigated the effectiveness of palliative radiation therapy for HCC bone metastasis. In this
study, 51 patients received radiation therapy for 77 bony metastatic lesions, with a median
total dose of 30 Gy. There was pain relief in 56 lesions (73%), however, median and 1 year
survival were only 5 months and 15%, respectively. In aggregate, these studies suggest that
recurrent metastatic HCC may be sensitive to palliative radiation therapy. Therefore, radiation
therapy should be considered for palliation of metastatic HCC lesions.
Abbreviation
HCC Hepatocellular carcinoma
HIF-1α Hypoxia-inducible factor 1, alpha
MELD Model for end-stage liver disease
RFA Radiofrequency ablation
PEI Percutaneous ethanol injection
TACE Transarterial chemoembolization
TGFβ Transforming growth factor-beta
TNM Classification of Malignant Tumors (Tumor, lymph Node, Metastasis)
VEGF Vascular endothelial growth factor
UNOS United Network for Organ Sharing
UCSF University of California, San Francisco
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